In vitro susceptibility of antimony-resistant Leishmania to alternative drugs.
D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000965:Antimony / Q000627:therapeutic use*; D005573:Formycins / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007654:Ketoconazole; D007896:Leishmaniasis / Q000188:drug therapy*; D010419:Pentamidine / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D005573:Formycins; D007093:Imidazoles; D010879:Piperazines; D010419:Pentamidine; D000666:Amphotericin B; D000965:Antimony; D007654:Ketoconazole